SILVER SPRING, Md. and
RESEARCH TRIANGLE PARK, N.C.,
Nov. 24, 2020 /PRNewswire/
-- United Therapeutics Corporation (Nasdaq: UTHR) today
announced the release of its initial Corporate Responsibility
Report with primarily 2019 data and selected 2020 highlights,
providing stakeholders important information regarding the
company's commitment to environmental, social, and governance (ESG)
priorities.
"Environmental sensitivity and corporate responsibility have
been part of our DNA since our inception," said Martine Rothblatt, Ph.D., Chairman and Chief
Executive Officer of United Therapeutics. "In light of growing
interest in ESG from investors and other stakeholders, we are
pleased to share our corporate responsibility achievements in this
inaugural report."
United Therapeutics developed its initial Corporate
Responsibility Report with guidance from members of its Board of
Directors and the frameworks provided by both the Global Reporting
Initiative (GRI) and Sustainability Accounting Standards Board
(SASB). United Therapeutics is using applicable GRI and SASB
metrics to measure its performance.
United Therapeutics plans to continue to report on its corporate
responsibility efforts on an annual basis and plans to issue its
next report around mid-year 2021.
Find the full report at corporateresponsibility.unither.com.
About United Therapeutics
United Therapeutics Corporation focuses on the strength of a
balanced, value-creating biotechnology model. We are confident in
our future thanks to our fundamental attributes, namely our
obsession with quality and innovation, the power of our brands, our
entrepreneurial culture, and our bioinformatics leadership. We also
believe that our determination to be responsible citizens – having
a positive impact on patients, the environment, and society – will
sustain our success in the long term.
Through our wholly owned subsidiary, Lung Biotechnology PBC, we
are focused on addressing the acute national shortage of
transplantable lungs and other organs with a variety of
technologies that either delay the need for such organs or expand
the supply. Lung Biotechnology is the first public benefit
corporation subsidiary of a public biotechnology or pharmaceutical
company.
Forward-looking Statements
Statements included in this press release that are not
historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, among others, statements
relating to our planned reporting on ESG matters, our ability to
create value and sustain our success in the long-term, and our
efforts to develop technologies that either delay the need for
transplantable organs or expand the supply of transplantable
organs. These forward-looking statements are subject to certain
risks and uncertainties, such as those described in our periodic
reports filed with the Securities and Exchange Commission, that
could cause actual results to differ materially from anticipated
results. Consequently, such forward-looking statements are
qualified by the cautionary statements, cautionary language and
risk factors set forth in our periodic reports and documents filed
with the Securities and Exchange Commission, including our most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,
and Current Reports on Form 8-K. We claim the protection of the
safe harbor contained in the Private Securities Litigation Reform
Act of 1995 for forward-looking statements. We are providing this
information as of November 24, 2020
and assume no obligation to update or revise the information
contained in this press release whether as a result of new
information, future events, or any other reason.
For Further Information Contact:
Dewey Steadman at (202) 919-4097
Email: ir@unither.com
View original
content:http://www.prnewswire.com/news-releases/united-therapeutics-releases-its-first-corporate-responsibility-report-301179114.html
SOURCE United Therapeutics Corporation